Earnings watch · CELC · Healthcare

Celcuity LLC (CELC) enters earnings with mixed weekly signals

A near-term rebound contrasts with deeper medium-term losses before the oncology biotech reports.

Celcuity LLC
Latest92.78 USD
1W move7.4%
Volume0.4x
TrendInactive
Oncology biotechnology lab with cancer research materials and financial market data screens.

Market update

What happened

Celcuity LLC (CELC) enters its Aug. 13 earnings date after a positive latest week but a damaged medium-term setup. The earnings calendar lists the fiscal period ending June 30 with a consensus estimate of -1.08 USD.

The chart is a weekly price path over 52 weeks, so the move is weekly context rather than live intraday action. Confirmation remains mixed, with an inactive trend state and negative pressure from Market Dynamics, while trading activity stayed below its 13-week norm.

Continue your research

Explore CELC across Sharemaestro

These links are shown because current Sharemaestro data is available for this company.

Interactive chartReview weekly price, Trend Line, Fair Value, volume and Relative Strength.Full weekly reportOpen the full company report, financial profile and peer comparison.Technical analysisExamine support, resistance, momentum and the current trend readings.Stage analysisSee whether the stock is basing, advancing, distributing or declining.Trend historyReview how long the current trend has persisted and where it has changed.Sector comparisonCompare sector returns, breadth, leaders and weaker areas.Industry comparisonSee how this company’s industry is performing across its members.Company factorsCompare value, quality, growth, momentum and financial strength.News sentimentSee the balance, quality and freshness of recent company coverage.Buying and selling pressureReview longer-term accumulation, distribution and reversal readings.EarningsReview report dates, estimates, past results and earnings surprises.Options activitySee options positioning, expected move and unusual trading activity.Short interestReview short positioning, crowding and possible squeeze risk.Insider transactionsSee reported purchases and sales by company directors and executives.

Biotechnology coverage

Evidence context